Clearmind Medicine and Aragen strike 'psychedelic' development and supply agreement
The CDMO's services will help to advance clinical testing of Clearmind's drug candidate for treating alcohol use disorder
Aragen Life Sciences has agreed to produce Clearmind Medicine's innovative molecule, 5-Methoxy-2-aminoindane (MEAI) ― a unique synthetic psychedelic molecule designed to treat alcohol use disorder and binge drinking.
As part of the development and supply agreement, CDMO Aragen will provide process optimisation and synthesis, GMP manufacturing and supply of MEAI to Clearmind.
Clearmind, which positions itself as a psychedelic pharmaceutical biotech, says its primary objective is to research and develop psychedelic-based compounds and attempt to commercialise them as regulated medicines, foods or supplements.
To date, the company has already received "extremely" favourable preclinical studies results, demonstrating a high safety profile and promising efficacy.
With Aragen's assistance, Clearmind is now preparing for pre-investigation new drug (IND) meeting, which will be followed by an IND and a clinical trial in the second half of 2022.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.